South Texas Accelerated Research Therapeutics, or START, and BGI Tech kicked off a project last week that aims to sequence at least 1,000 and potentially up to 10,000 cancer genomes from patients at primary diagnosis and correlate the genomic alterations with extensive clinical outcome data about the patients' drug regimen and disease progression.

The goal of the project is to aid cancer drug development by identifying both new targets as well as gaining a better understanding of response and resistance to existing drugs.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

The Kansas City Star examines issues surrounding newborn genome sequencing.

Researchers say their Research Resource Identifier citation format is catching on, Nature News reports.

In Science this week: the Human Silencing Hub protein complex, and more.

Heads of various research funding agencies discuss how to encourage scientific breakthroughs, ScienceInsider reports.